These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 12039497)

  • 1. Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up.
    Schläpfer J; Rapp F; Kappenberger L; Fromer M
    J Am Coll Cardiol; 2002 Jun; 39(11):1813-9. PubMed ID: 12039497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amiodarone therapy for sustained ventricular tachycardia after myocardial infarction: long-term follow-up, risk assessment and predictive value of programmed ventricular stimulation.
    Maury P; Zimmermann M; Metzger J; Reynard C; Dorsaz P; Adamec R
    Int J Cardiol; 2000; 76(2-3):199-210. PubMed ID: 11104875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients with life-threatening sustained ventricular tachyarrhythmias--the role of guided antiarrhythmic drug therapy.
    Steinbeck G; Greene HL
    Prog Cardiovasc Dis; 1996; 38(6):419-28. PubMed ID: 8638023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
    Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
    Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study.
    Cappato R
    Am J Cardiol; 1999 Mar; 83(5B):68D-73D. PubMed ID: 10089843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
    Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
    Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amiodarone: clinical trials.
    Naccarelli GV; Wolbrette DL; Patel HM; Luck JC
    Curr Opin Cardiol; 2000 Jan; 15(1):64-72. PubMed ID: 10666663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia; long-term outcome in relation to acute electrophysiological findings.
    Della Bella P; De Ponti R; Uriarte JA; Tondo C; Klersy C; Carbucicchio C; Storti C; Riva S; Longobardi M
    Eur Heart J; 2002 Mar; 23(5):414-24. PubMed ID: 11846499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amiodarone: what have we learned from clinical trials?
    Naccarelli GV; Wolbrette DL; Dell'Orfano JT; Patel HM; Luck JC
    Clin Cardiol; 2000 Feb; 23(2):73-82. PubMed ID: 10676597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implanted cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias.
    Saksena S; Madan N; Lewis C
    Prog Cardiovasc Dis; 1996; 38(6):445-54. PubMed ID: 8638025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.
    Epstein AE; Abraham WT; Bianco NR; Kern KB; Mirro M; Rao SV; Rhee EK; Solomon SD; Szymkiewicz SJ
    J Am Coll Cardiol; 2013 Nov; 62(21):2000-2007. PubMed ID: 23916930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A; Sapp J
    Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate?
    Liang JJ; Hodge DO; Mehta RA; Russo AM; Prasad A; Cha YM
    Europace; 2014 Dec; 16(12):1759-66. PubMed ID: 25100756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?
    Block M; Hammel D; Böcker D; Borggrefe M; Breithardt G
    Am J Cardiol; 1996 Sep; 78(5A):62-8. PubMed ID: 8820838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.